Fran Brown, PhD
Senior Vice President, Global Head, Drug Development ScienceFran has over 25 years of experience with strategic and operational global drug development from early discovery to filing and post-marketing. She possesses a broad knowledge of strategic drug discovery and development, with a special focus on development strategy and the application of model-informed drug development (MIDD).
Managing Director, Technomark Life Sciences
Allen Hakimi, Managing Director and CEO of Technomark. Mr. Hakimi joined Technomark Consulting Service Ltd. in the UK in 2006 and has successfully led its corporate transition to Technomark Life Sciences, which now invests via a co-development business model, by sharing the cost of pre-clinical development in exchange for downstream remuneration. Under this new co-funding model, Technomark has invested in 14 development programs, with successful exits of three programs through large pharma (Wyeth/Pfizer, BMS, D-Pharm Israel), and a fourth through IPO.
Senior Associate / EIR, Xontogeny
Jayanth is a Senior Associate at Xontogeny leveraging his diverse skill set to aid the due diligence efforts of the Xontogeny investment team.
Jayanth is experienced in building up multiple biotech and medtech ideas including cell therapies (cancer & autoimmune), engineered enzymes & antibodies, core needle biopsy devices, infectious disease diagnostics, and urinary microvalves. Over the course of advancing prior projects, Jay has been involved with TuckLab and Tuck-Magnuson Startup Incubator and is driven to aid in the advancement of biomedical innovations.
Jayanth received an AB degree in Economics from Dartmouth College, a BE degree in Biomedical Engineering and MEng degree in Biological/Chemical Engineering from Dartmouth’s Thayer School of Engineering. While at Dartmouth, Jay was an active member of the Dartmouth Entrepreneurial Network (DEN) Associates/Magnuson Center Student Leadership Board.
